Acrux Targets $2.9B Female Testosterone Market with Co-Development Strategy

Acrux’s Bold Pivot into Women’s Sexual Health

Acrux Limited (ASX:ACR) has unveiled a transformative strategy pivot, shifting its focus from a broad topical generics portfolio to the development and commercialisation of a Female Testosterone treatment aimed at Hypoactive Sexual Desire Dysfunction (HSDD). This condition affects an estimated 4.9 million menopausal women in the US alone, representing a significant unmet medical need and a potential market exceeding US$2.8 billion annually.

The move follows a comprehensive review led by new CEO John Warmbrunn and his executive team, who have identified the company’s unique position to capitalise on its transdermal drug delivery expertise and existing FDA regulatory engagement. Acrux’s Female Testosterone product is designed to be a "patchless" metered dose transdermal system (MDTS) spray, applied to the abdomen, mitigating risks of incidental transfer and aligning with patient preferences.

Warmbrunn emphasised the opportunity: "Our proven capability in registering and commercialising products gives us great confidence that we can gain an early mover advantage." With no current FDA-approved Female Testosterone treatment for HSDD in the US, Acrux aims to fill this void and leverage long-standing relationships with potential co-development partners to expedite market entry.

Clinical and Regulatory Momentum

Acrux’s Female Testosterone candidate has completed Phase I and II clinical trials, demonstrating a strong safety profile and efficacy signals without material adverse events. The FDA has provided clear guidance on the pathway to Phase III, which the company plans to pursue through a co-development model with a global partner. This approach is designed to de-risk the regulatory process and leverage partner expertise in clinical trial execution, sales force access, and market education.

The regulatory backdrop has evolved favorably, with recent approvals of HSDD treatments in markets including the UK, Australia, New Zealand, and South Africa. Acrux submitted a Pre-IND package to the FDA in October 2025, and regulatory pathways were clarified in early 2026. The company’s proprietary 505 (b)(2) exclusivity and decades of transdermal formulation know-how underpin its confidence in securing a competitive position.

Professor Susan R Davis, a leading expert in women’s health, highlighted testosterone’s role beyond male physiology: "There is irrefutable evidence that testosterone therapy in doses within the physiological range improves sexual desire and reduces distress in postmenopausal women with HSDD." Acrux’s product aims to harness this clinical validation with a patient-preferred delivery system.

Supporting Revenue and Strategic Partnerships

Acrux’s existing portfolio of topical generics, including FDA-registered products like Nitroglycerin ointment and Dapsone gels, continues to generate revenue that subsidises ongoing R&D. The company reported a surge in generics licensing income, projected to increase 449% year-on-year in FY26, providing a stable financial base for its pivot.

This financial underpinning was bolstered by recent divestments of underperforming assets, such as Prilocaine and Lidocaine creams, freeing resources to focus on higher-value hormone therapies. The company’s strategic approach to co-development partnerships is built on extensive existing relationships, aiming for a Phase III trial commencement by early FY27 and a product launch targeted for early FY29.

Analysts will note this follows Acrux’s earlier moves to boost hormone therapy development, including securing a $0.55 million R&D tax incentive advance to accelerate clinical progress R&D Tax Incentive boost and expanding its US footprint with growing topical generics sales US footprint and hormone therapy growth.

Market Potential and Patient Impact

HSDD is a prevalent condition characterized by low sexual desire causing personal distress, affecting approximately 10% of adult women globally. Beyond sexual health, untreated HSDD can contribute to low self-esteem, depression, and interpersonal difficulties. Clinical trials have shown that testosterone therapy can improve sexual function in over half of treated women within 6 to 8 weeks, with ancillary benefits including mood and cognitive improvements.

The US market alone is estimated to have around 12 million women suffering from HSDD, with 2 million currently using off-label testosterone treatments. Acrux’s strategy aims to capture this underserved population with a regulated, approved therapy, potentially setting a new standard in women’s health treatment.

Globally, the condition’s prevalence is expected to grow, with approximately 130,000 women entering menopause daily by 2030, underscoring the long-term growth potential for Acrux’s product.